First Time Loading...

Dechra Pharmaceuticals PLC
LSE:DPH

Watchlist Manager
Dechra Pharmaceuticals PLC Logo
Dechra Pharmaceuticals PLC
LSE:DPH
Watchlist
Price: 3 866 GBX Market Closed
Updated: May 10, 2024
Section:
 

Relative Value

The Relative Value of one DPH stock under the Base Case scenario is 102.53 GBX. Compared to the current market price of 3 866 GBX, Dechra Pharmaceuticals PLC is Overvalued by 97%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

DPH Relative Value
Base Case
102.53 GBX
Overvaluation 97%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

578.3
P/S
P/S
Price to Sales
578.3
vs History
63
vs Industry
1
Median 3Y
578.3
Median 5Y
620.7
Industry
2.5
Forward
517.3
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
2
Median 3Y
6 502.3
Median 5Y
8 756.2
Industry
23.4
Forward
2 980
More Details
6 923.9
P/OCF
P/OCF
Price to OCF
6 923.9
vs History
0
vs Industry
0
Median 3Y
4 923.2
Median 5Y
3 818.7
Industry
17.4
More Details
2 143.3
P/FCFE
P/FCFE
Price to FCFE
2 143.3
vs History
47
vs Industry
0
Median 3Y
2 112.3
Median 5Y
2 143.3
Industry
23.6
More Details
583.1
P/B
P/B
Price to Book Value
583.1
vs History
50
vs Industry
0
Median 3Y
583.1
Median 5Y
587.4
Industry
2.1
More Details
578.8
EV/S
EV/S
Enterprise Value to Sales
578.8
vs History
63
vs Industry
1
Median 3Y
578.8
Median 5Y
621.2
Industry
2.6
Forward
517.8
More Details
1 026
EV/GP
EV/GP
Enterprise Value to Gross Profit
1 026
vs History
60
vs Industry
0
Median 3Y
1 026
Median 5Y
1 082.3
Industry
5.2
More Details
3 846.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
3 846.3
vs History
49
vs Industry
0
Median 3Y
3 768.8
Median 5Y
3 846.3
Industry
13.7
Forward
1 926.1
More Details
17 702.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
17 702.3
vs History
0
vs Industry
100
Median 3Y
5 776.2
Median 5Y
5 693.6
Industry
17.2
Forward
2 795.1
More Details
6 930.6
EV/OCF
EV/OCF
Enterprise Value to OCF
6 930.6
vs History
0
vs Industry
0
Median 3Y
4 928
Median 5Y
3 820.3
Industry
16.2
More Details
13 236.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
13 236.9
vs History
0
vs Industry
0
Median 3Y
8 626.4
Median 5Y
6 442.2
Industry
17.8
More Details
326.4
EV/IC
EV/IC
Enterprise Value to IC
326.4
vs History
65
vs Industry
0
Median 3Y
326.4
Median 5Y
352.5
Industry
2
More Details

Multiples Across Competitors

DPH Competitors Multiples
Dechra Pharmaceuticals PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
729.1B USD 20.3 118.5 58.2 66.2
DK
Novo Nordisk A/S
CSE:NOVO B
3.9T DKK 16.1 44.1 32.9 36.1
US
Johnson & Johnson
NYSE:JNJ
359.9B USD 4.2 9.4 11.5 15
US
Merck & Co Inc
NYSE:MRK
330.2B USD 5.4 143.2 35.7 58.2
UK
AstraZeneca PLC
LSE:AZN
191.8B GBP 5 37.9 174.6 278.6
CH
Roche Holding AG
SIX:ROG
180.2B CHF 3.1 15.7 8.9 10.6
CH
Novartis AG
SIX:NOVN
180.3B CHF 3.4 11.4 8.6 12.6
US
Pfizer Inc
NYSE:PFE
158.4B USD 2.9 -512.4 12.7 20.3
FR
Sanofi SA
PAR:SAN
118.3B EUR 1.7 13.1 6 7.8
P/E Multiple
Earnings Growth
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Average P/E: 49.1
Negative Multiple: -15 783.5 		N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
118.5
346%
DK
Novo Nordisk A/S
CSE:NOVO B
44.1
84%
US
Johnson & Johnson
NYSE:JNJ
9.4
-20%
US
Merck & Co Inc
NYSE:MRK
143.2
7 454%
UK
AstraZeneca PLC
LSE:AZN
37.9
168%
CH
Roche Holding AG
SIX:ROG
15.7
26%
CH
Novartis AG
SIX:NOVN
11.4
15%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -512.4
680%
FR
Sanofi SA
PAR:SAN
13.1
120%

See Also

Summary
DPH intrinsic value, competitors valuation, and company profile.
DCF Valuation
DPH stock valuation using Discount Cash Flow valuation method.
Relative Valuation
DPH stock valuation using valuation multiples.
Wall Street Estimates
DPH price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
DPH stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 136,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.